Predictive Oncology (POAI) Competitors

Predictive Oncology (NASDAQ:POAI) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, community ranking, valuation, media sentiment, earnings and analyst recommendations.

Does the media prefer POAI or NEPH?

In the previous week, Predictive Oncology had 11 more articles in the media than Nephros. MarketBeat recorded 12 mentions for Predictive Oncology and 1 mentions for Nephros. Nephros' average media sentiment score of 0.98 beat Predictive Oncology's score of 0.02 indicating that Nephros is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Predictive Oncology	0 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Nephros	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Do analysts rate POAI or NEPH?

Predictive Oncology currently has a consensus target price of $3.00, suggesting a potential upside of 359.70%. Nephros has a consensus target price of $5.00, suggesting a potential upside of 214.47%. Given Predictive Oncology's higher possible upside, research analysts clearly believe Predictive Oncology is more favorable than Nephros.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00
Nephros	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has better earnings and valuation, POAI or NEPH?

Nephros has higher revenue and earnings than Predictive Oncology. Nephros is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.78M	2.45	-$13.98M	-$3.05	-0.21
Nephros	$14.24M	1.18	-$1.58M	-$0.09	-17.67

Is POAI or NEPH more profitable?

Nephros has a net margin of -6.86% compared to Predictive Oncology's net margin of -1,012.32%. Nephros' return on equity of -11.39% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-1,012.32%	-286.30%	-122.11%
Nephros	-6.86%	-11.39%	-8.30%

Do insiders & institutionals believe in POAI or NEPH?

9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 41.1% of Nephros shares are held by institutional investors. 3.4% of Predictive Oncology shares are held by insiders. Comparatively, 4.1% of Nephros shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Does the MarketBeat Community believe in POAI or NEPH?

Predictive Oncology received 136 more outperform votes than Nephros when rated by MarketBeat users. Likewise, 64.22% of users gave Predictive Oncology an outperform vote while only 43.33% of users gave Nephros an outperform vote.

Company	Underperform	Outperform
Predictive Oncology	Outperform Votes 149 64.22%	Underperform Votes 83 35.78%
Nephros	Outperform Votes 13 43.33%	Underperform Votes 17 56.67%

Which has more volatility & risk, POAI or NEPH?

Predictive Oncology has a beta of 1.14, meaning that its share price is 14% more volatile than the S&P 500. Comparatively, Nephros has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500.

Summary

Nephros beats Predictive Oncology on 12 of the 18 factors compared between the two stocks.